Onconetix, Inc. has announced the completion of a one-for-ten reverse stock split, a strategic move aimed at increasing the market value of its shares. The decision, approved by the Board of Directors, is designed to enhance the company’s appeal to institutional investors and stabilize its stock price.

The reverse stock split took effect on November 6, 2026, reducing the number of outstanding shares from approximately 6.7 million to about 670,000. This adjustment is intended to streamline the company’s capital structure and potentially make its stock more attractive to investors.

Background

Onconetix, Inc. operates in the pharmaceutical preparations sector, specifically focusing on innovative therapies. The company is traded on the Nasdaq under the ticker symbol ONCO. It was formerly known as Blue Water Biotech, Inc., having undergone a name change earlier this year.

What the Filing Says

According to the recent SEC filing, "As a result of the Reverse Stock Split, the number of outstanding shares of Common Stock was reduced from approximately 6.7 million shares to approximately 670,000 shares." The filing further clarifies that stockholders entitled to fractional shares will receive cash payments instead.

Impact

This reverse stock split is expected to affect current shareholders, as their holdings will be consolidated into fewer shares. It may also impact potential investors and institutional stakeholders who may find the adjusted share price more palatable. Additionally, this move could influence how competitors in the pharmaceutical preparations industry approach their own stock management strategies.

What's Next

The filing does not say what happens next.